CMS Works Toward Additional Compendia For Off-Label Cancer Drug Coverage
Executive Summary
The Centers for Medicare & Medicaid Services aims to solicit public comments within the next several weeks on proposed criteria and processes for identifying compendia to be used by Medicare Part B contractors in making local coverage determinations for off-label cancer drugs and biologicals
You may also be interested in...
UnitedHealth To Rely On NCCN Compendium For Off-Label Oncology Coverage
UnitedHealth is streamlining its payment process for off-label use of oncology drugs by designating the recommendations of the National Comprehensive Cancer Network's medical compendium as its official reference
UnitedHealth To Rely On NCCN Compendium For Off-Label Oncology Coverage
UnitedHealth is streamlining its payment process for off-label use of oncology drugs by designating the recommendations of the National Comprehensive Cancer Network's medical compendium as its official reference
Part B Drug Compendia For Off-Label Chemotherapy May Be Updated Annually
CMS will annually solicit public comment on updating the list of compendia used by Medicare Part B contractors in making local coverage determinations for off-label cancer drugs and biologicals, according to a proposed rule scheduled for July 12 publication in the Federal Register